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ABSTRACT 
The purpose of this research is to prepare metformin hydrochloride immediate release tablets by wet 
granulation technique. In order to obtain the best, optimized product ten different formulations were 
developed. Different binder, disintegrants and lubricants taken as variables. Weight variation, 
thickness, hardness, friability, disintegration time, in-vitro release and pharmaceutical assay were 
studied as response variables. Capping was observed in formulation containing PVP K-30. However, 
in the remaining formulation containing PVP K-90, no capping was observed. The formulation A7 
was selected as optimized formulation. The different physical properties and in-vitro release profile 
showed best comparable with the reference product. Optimization has proven an effective tool in 
product development. 
Keywords: Metformin hydrochloride, optimization, anti-diabetic drug. 
 
1. Introduction 
Oral route of drug administration is perhaps 
the most appealing route for the delivery of 
drugs. Various dosage forms administered 
orally, the tablet is one of the most preferred 
dosage forms because of its ease of 
manufacturing, convenience in administration, 
accurate dosing, stability compared with oral 
liquids, and because it is more tamperproof 
than capsules1-2. The bioavailability of drug is 
dependent on in vivo disintegration, 
dissolution, and various physiological factors. 
In recent years, scientists have focused their 
attention on the formulation of quickly 
disintegrating tablets. The task of developing 
rapidly disintegrating tablets is accomplished 
by using a suitable diluent and super 
disintegrants. The gastrointestinal tract 
provides sufficient fluid to facilitate 
disintegration of the dosage form and 
dissolution of the drug. The large surface area 
of gastric mucosa favors the drug absorption. 
Therefore, the oral route has continued to be 
the most appealing route for drug delivery 
despite the advancements made in the new 
drug delivery systems. Banker and Anderson 
stated that at least 90% of all drugs used to 
produce systemic effect are administered 
orally3. 
Metformin is an oral anti-diabetic drug from 
the biguanide class. It is the first-line drug for 
the treatment of type-II diabetes, particularly 
in overweight and obese people and those with 
normal kidney function, and evidence suggests 
it may be the best choice for people with heart 
failure3-4. 
The main use for metformin is in the treatment 
of diabetes mellitus Type-II, especially when 
this accompanies obesity and insulin resistance. 
metformin is the only anti-diabetic drug that has 
been proven to protect against the cardiovascular 
complications of diabetes. This was first shown 
in the United Kingdom Prospective Diabetes 
Study, a large study of overweight patients with 
diabetes. Unlike the other most-commonly 
prescribed class of oral diabetes drugs, the 
sulfonylurea, metformin (taken alone) does not 
induce hypoglycemia. Hypoglycemia during 
intense exercise has been documented, but is 
extremely rare. It also does not cause weight 
gain, and may indeed produce minor weight 
loss. metformin also modestly reduces LDL and 
triglyceride levels. 
Despite decades of clinical use, the molecular 
mechanisms by which metformin acts still have 
not been definitively determined and many more 
mechanisms will be elucidated. Unlike 
secretagogues, metformin has no effect on 
plasma insulin concentration increases, and due 
to reduction in glucotoxicity it has an indirect 
effect on beta cell secretory function5. 
The objective of the present study was to 
develop Telmisartan (IR) immediate release 
tablets using super disintegrants like 
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croscarmellose sodium and sodium starch 
glycolate, which is best comparable with the 
innovator product by varying different 
excipients. 
 
2. Materials and Methods 
2.1 Materials: Metformin hydrochloride, 
sodium starch glycolate, croscarmellose sodium, 
povidone k-30, povidone k-90, 
hypromellose2910 (6cps), magnesium stearate, 
sodium stearyl fumarate, microcrystalline 
cellulose and PEG-400 were obtained from 
Torrent Research Centre, Gandhinagar. All 
reagents and solvents used were of analytical 
grade satisfying pharmacopoeial standards. 
2.2 Methods. 
2.2.1 Preparation of Metformin HCl 
Immediate Release Tablets: Wet granulation 
technique will ensure uniform distribution of 
drug as well as improve flow property. 
Therefore, this approach was carry forward for 
formulation development of metformin Tablets. 
2.2.2 Granulation: Granules were prepared by 
using the rapid mixture granulator. Binder 
solution was added to the dry mix of the drug 
and excipients for 2-3 mins with impeller fast 
and chopper off. Kneading was given for 1-2 
minutes with impeller fast and chopper fast. 
2.2.3 Drying: Wet mass was dried at inlet air 
temperature 45 º ± 7 ºC till to get LOD NMT 
1.5% w/w. 
Sizing:  Granules were passed through 
Oscillating granulated fitted with 0.8 mm SS 
Screen of oscillating granulator. The granules 
were collected into poly bag. Yield of sized 
granules was recorded and particle size 
distribution test was performed. 
2.2.4 Final mixing and Tablet compression: 
Screened granules were finally blended with 
lubricants using a suitable mixer with a 
revolution of 10 rpm for about 15 min thus 
producing the final mixture. Using a suitable 
rotary tablet press the final mixture for tablet 
compression is compressed into tablets. The 
target weight is 720 mg containing metformin 
HCl (500 mg). 
Dissolution profiles of different formulation are 
summarized in Figure. 1 and 2. Formulation A1 
and A2 showed slow disintegration and also 
delayed in dissolution. Formulation A3, A4 and 
A5 were prepared with different disintegrants 
with different concentration. Trial batch A5 
showed good disintegration and dissolution i.e. 
83.4 % in 0.1 N  
 
Parameters A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 
Disintegration 
(min) 8 8 5-6 5 -6 4 4 3 3-4 4-5 4-5 
Hardness (N) 128.9 131.5 138.5 136.4 136.4 138.9 141.5 142.9 141.5 141.8 
Friability (%) 0.07 0.09 0.07 0.09 0.09 0.09 0.08 0.09 0.08 0.10 
Assay (%) 94.5 97.3 95.2 97.6 98.5 98.1 97.6 95.1 94.2 96.1
Weight of the 
tablet (mg)* 721.4 720.6 720.2 721.6 720.8 720.6 720.2 721.2 720.8 720.14 
 
*Average of 10 tablets 
 
Ingredients (mg) A1 A2 A3 A4 A5 A6 A7 A8 A9 A10 
Metformin HCl 500 500 500 500 500 500 500 500 500 500 
Microcrystalline 
cellulose 150 -- 150 150 140 140 130 130 122 122 
Dibasic calcium 
phosphate -- 150 -- -- -- -- -- -- -- -- 
Croscarmellose sodium 32 32 12 32 42 42 42 42 42 42 
Sodium starch glycolate -- -- 20 -- -- -- -- -- -- -- 
Povidone k-30 30 30 30 30 30 -- --    
Povidone k-90 -- -- -- -- -- 30 40 40 40 40
Water qs qs qs qs qs qs qs qs qs qs 
Magnesium stearate 8 8 8 8 8 8 8 -- 16 -- 
Sodium stearyl 
fumarate -- -- -- -- -- -- -- 8 -- 16 
Total  720 720 720 720 720 720 720 720 720 720 
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2.3 Stability Study 
The selected batch (A7) was kept at 40°C with 
75% RH and the samples were withdrawn at 30 
and 60 days for physical and in vitro evaluation 
of drug release 6 . 
 
3. Result and Discussion 
All the tablet formulations showed acceptable 
pharmacotechnical properties and complied with 
the range specified by US Pharmacopoeia for 
Disintegration, weight variation, friability, 
hardness, LOD and Water Content. (Shown in 
Table 3) 
HCl Trial batch A6 and A7 were taken with 
sized API through 0.3 mm and 0.5 mm screen.  
Batch A7 gives better dissolution and 
disintegration. Trial batch A8, A9 and A10 were 
taken with different concentration of lubricant 
extragranularly. Here we found one important 
observation that increased quantity of lubricant 
produce poor release at last point of time 
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Figure 1 Comparative Dissolution Study of 
A1 to A5 
COMARATIVE DISSOLUTION STUDY OF 
DIFFERENT TRIAL BATCHES IN 0.1N HCL 
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Figure 2 Comparative Dissolution Study of 
A6 to A10 
 
Figure 3 Comparison of dissolution profile of 
optimized batch with marketed formulation. 
 
Dissolution profile of optimized batch A7 compared 
with dissolution profile of marketed formulation, 
indicated in Figure 9.7 and 9.8. 
 
The formulations had a residual drug content of 
more than 100% after 1 month when stored at 
40° C / 75 % RH. These results indicated that 
the selected formulation is stable. Also, the aged 
samples showed no change in the physical 
appearance, hardness or drug content. 
 
Conclusion 
The drug release profile for batch A7 (almost 
similar to the innovator) as indicated by very 
high F2 value (similarity factor), very low F1 
value (dissimilarity factor) and other physical 
attributes of the dosage form. 
This tablet can be commercial by making 
various optimizations in the present formulation. 
The in-vivo drug release can be checked and 
toxicity study maybe also carried out. By 
making the combination with some new drug the 
novel formulation can be developed. 
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